18 results on '"Lakkis, Nasser"'
Search Results
2. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes.
- Author
-
Sarkiss MG, Yusuf SW, Warneke CL, Botz G, Lakkis N, Hirch-Ginsburg C, Champion JC, Swafford J, Shaw AD, Lenihan DJ, and Durand JB
- Subjects
- Acute Disease, Aged, Coronary Disease drug therapy, Coronary Disease etiology, Female, Hemorrhage complications, Humans, Male, Medical Records, Myocardial Infarction drug therapy, Myocardial Infarction etiology, Outcome Assessment, Health Care, Platelet Count, Retrospective Studies, Survival Rate, Thrombocytopenia drug therapy, Thrombocytopenia etiology, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Aspirin therapeutic use, Coronary Disease prevention & control, Myocardial Infarction prevention & control, Neoplasms complications, Thrombocytopenia prevention & control
- Abstract
Background: Patients with cancer who have thrombocytopenia may experience acute coronary syndromes (ACS), and the use of aspirin (ASA) poses an increased risk of bleeding. The purpose of this study was to test the hypothesis that the benefit of ASA therapy in the treatment of ACS would extend to cancer patients with thrombocytopenia and outweigh the risks of severe bleeding., Methods: The records of all cancer patients diagnosed with an ACS in 2001 and referred for cardiology consultation were reviewed. Patients were divided into 2 groups on the basis of platelet count, >100 cells k/microL and < or = 100 cells k/microL. Data were collected on the use of ASA therapy, bleeding complications, and survival rates. The authors assessed group differences by using the Wilcoxon rank sum test or 2-tailed Fisher exact test, as appropriate. Univariate and multivariate logistic regression models were used to assess factors potentially associated with 7-day survival., Results: In cancer patients with ACS and thrombocytopenia, those who did not receive ASA had a 7-day survival rate of 6% compared with 90% in those who did receive ASA (P < .0001). There were no severe bleeding complications. Patients with a platelet count (>100 cells k/microL) who received ASA had a 7-day survival rate of 88% compared with 45% in those who did not receive ASA (P = .0096)., Conclusions: Therapy with ASA was associated with a significantly improved 7-day survival after ACS in cancer patients, with or without thrombocytopenia, and not associated with more severe bleeding., ((c) 2007 American Cancer Society.)
- Published
- 2007
- Full Text
- View/download PDF
3. Impact of adenosine diphosphate and calcium chelation on platelet aggregation testing in patients receiving clopidogrel therapy.
- Author
-
Patel P, Gonzalez R, Dokainish H, and Lakkis N
- Subjects
- Adenosine Diphosphate administration & dosage, Amino Acid Chloromethyl Ketones pharmacology, Chelating Agents pharmacology, Citrates pharmacology, Clopidogrel, Coronary Disease physiopathology, Cysteine Proteinase Inhibitors pharmacology, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Platelet Function Tests, Sodium Citrate, Ticlopidine therapeutic use, Adenosine Diphosphate pharmacology, Coronary Disease drug therapy, Platelet Aggregation drug effects, Platelet Aggregation Inhibitors therapeutic use, Ticlopidine analogs & derivatives
- Published
- 2006
- Full Text
- View/download PDF
4. Effectiveness of percutaneous intervention for patients with obstructive hypertrophic cardiomyopathy and coronary artery disease.
- Author
-
Nambi V, Buergler JM, Lakkis NM, Franklin J, Spencer WH 3rd, and Nagueh SF
- Subjects
- Adult, Aged, Aged, 80 and over, Cardiomyopathy, Hypertrophic complications, Cardiomyopathy, Hypertrophic diagnosis, Coronary Disease complications, Coronary Disease diagnosis, Echocardiography, Doppler, Echocardiography, Stress, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Severity of Illness Index, Stroke Volume, Tomography, Emission-Computed, Single-Photon, Treatment Outcome, Angioplasty, Balloon, Coronary, Cardiomyopathy, Hypertrophic therapy, Coronary Disease therapy, Ethanol therapeutic use, Heart Septum drug effects, Solvents therapeutic use
- Abstract
Seven patients with obstructive hypertrophic cardiomyopathy and single-vessel coronary artery disease underwent percutaneous revascularization of the coronary lesion in addition to alcohol septal ablation therapy for dynamic outflow tract obstruction. One year later, there was a significant reduction of dynamic left ventricular outflow tract obstruction and no clinical evidence of restenosis.
- Published
- 2005
- Full Text
- View/download PDF
5. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban.
- Author
-
Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin KC, Aggarwal A, Kabbani SS, and DiBattiste PM
- Subjects
- Dose-Response Relationship, Drug, Flow Cytometry, Humans, Platelet Aggregation Inhibitors blood, Radioimmunoassay, Tirofiban, Tyrosine analogs & derivatives, Tyrosine blood, Coronary Disease drug therapy, Platelet Aggregation drug effects, Platelet Aggregation Inhibitors therapeutic use, Tyrosine therapeutic use
- Published
- 2003
- Full Text
- View/download PDF
6. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes.
- Author
-
Kleiman NS, Lakkis N, Cannon CP, Murphy SA, DiBattiste PM, Demopoulos LA, Weintraub WS, and Braunwald E
- Subjects
- Acute Disease, Aged, Coronary Angiography, Coronary Disease diagnostic imaging, Creatine Kinase, MB Form, Female, Humans, Male, Middle Aged, Outcome Assessment, Health Care, Predictive Value of Tests, Prospective Studies, Risk Assessment, Syndrome, Time Factors, Coronary Disease blood, Coronary Disease surgery, Creatine Kinase blood, Isoenzymes blood, Myocardial Revascularization adverse effects, Troponin T blood
- Abstract
Objective: We sought to determine whether elevation of plasma creatine kinase muscle-brain fraction (CK-MB) would be useful to triage patients with acute coronary syndromes (ACS) to early angiography/revascularization., Background: It is unknown whether the measurement of CK-MB is effective for triage to an aggressive management strategy., Method: Patients in the Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy (TACTICS-TIMI) 18 study received aspirin, heparin, and tirofiban for treatment of ACS, were randomized to an invasive or a conservative strategy (angiography/revascularization between 4 and 48 h), and were followed up for a composite end point of death, myocardial infarction, or rehospitalization for ACS. Of 2,220 patients, CK-MB was elevated in 826 (37%). Of the patients with negative CK-MB, troponin T was elevated in 361 (31.2%). Event rates at 30 and 180 days were twice as high in patients with elevated CK-MB than in patients without elevated CK-MB. Both groups had similar benefit from an invasive strategy; there was no evidence of interaction between CK-MB elevation and strategy on the composite end point at 30 or 180 days. When patients were stratified according to both CK-MB and troponin status, there was evidence of a benefit in the invasive strategy among patients who were CK-negative but troponin-positive (odds ratios [95% confidence interval]: 0.13 [0.04 to 0.39] at 30 days and 0.29 [0.16 to 0.52] at 180 days)., Conclusion: Patients with minimal amounts of recent onset myonecrosis but elevated risk as indicated by CK-MB and troponin, respectively, benefit most from invasive management. Determination of troponin levels yielded significant information regarding triage to an invasive strategy, particularly in CK-MB-negative patients.
- Published
- 2002
- Full Text
- View/download PDF
7. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.
- Author
-
Lakkis N, Lakiss N, Bobek J, and Farmer J
- Subjects
- Cardiac Catheterization, Female, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors administration & dosage, Platelet Aggregation Inhibitors therapeutic use, Platelet Function Tests, Radiology, Interventional, Tirofiban, Tyrosine therapeutic use, Coronary Disease therapy, Platelet Glycoprotein GPIIb-IIIa Complex antagonists & inhibitors, Tyrosine administration & dosage, Tyrosine analogs & derivatives
- Abstract
Platelet inhibition is central to the efficacy of the intravenous glycoprotein IIb/IIIa receptor inhibitors. Differences in the degree of platelet inhibition achieved with these agents may account for the disparity in clinical efficacy noted in recently completed clinical trials. The purpose of this study was to evaluate ex vivo platelet inhibition with tirofiban in patients admitted with acute coronary syndrome and who were referred for percutaneous coronary interventions. Twenty-five patients were studied. Ten patients received tirofiban 10 microg/kg bolus and 0.15 microg/kg infusion for 16 hr. Platelet inhibition was determined at 5, 15, 30, 45, 60, and 120 min after tirofiban, by light transmission aggregometry (LTA), rapid platelet function assay (RPFA), and platelet works (PW). The average platelet inhibition using RPFA with PPACK, was 87% at 5 min, then decreased to a nadir of 72% at 30 min and recovered back to > 80% at 60 min and onward. Similar trends were noted with RPFA-citrate, PW, and LTA. Ca-chelating anticoagulants (EDTA and citrate) overestimated platelet inhibition at all time points. Dose adjustment was done by increasing the bolus (15 microg/kg) in five patients, increasing the maintenance dose (0.2 microg/kg/min) in five patients, and increasing both the bolus and the maintenance dose in another five patients. Platelet inhibition tested by all the above methods was consistently over 90% when both the bolus and maintenance doses were increased. No increased incidence of major bleeding was noted at this adjusted dose. The current dosing of tirofiban may be inadequate to achieve appropriate platelet inhibition during PCI in patients admitted with acute coronary syndrome and receiving tirofiban immediately before the procedure in the cardiac catheterization laboratory. Dose adjustment may be needed to maximize platelet inhibition early during PCI., (Copyright 2002 Wiley-Liss, Inc.)
- Published
- 2002
- Full Text
- View/download PDF
8. Update on the Association of Inflammation and Atrial Fibrillation.
- Author
-
PATEL, PARAG, DOKAINISH, HISHAM, TSAI, PETER, and LAKKIS, NASSER
- Subjects
ADRENOCORTICAL hormones ,HORMONE therapy ,ACE inhibitors ,ANTIHYPERTENSIVE agents ,STATINS (Cardiovascular agents) ,CORONARY disease ,ANIMAL experimentation ,ATRIAL fibrillation ,BIOMARKERS ,C-reactive protein ,INFLAMMATION ,INTERLEUKINS ,BLOOD ,PATHOLOGICAL physiology ,DRUG therapy - Abstract
Update on the Association of Inflammation and Atrial Fibrillation. Atrial fibrillation (AF) is a common arrhythmia and is associated with significant morbidity and mortality. The pathogenesis of AF remains incompletely understood and management remains a difficult task. Over the past decade there has been accumulating evidence implicating inflammation in the pathogenesis of AF. Inflammation appears to play a significant role in the initiation and perpetuation of AF as well as the prothrombotic state associated with AF. Inflammatory biomarkers (C-reactive protein and interleukin-6) have been shown to be associated with the future development, recurrence and burden of AF, and the likelihood of successful cardioversion. Therapies directed at attenuating the inflammatory burden appear promising. Animal and clinical studies have evaluated statins, angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers, and corticosteroids for the treatment or prevention of AF. The purpose of this review is to provide current evidence on the relationship between inflammation and AF and potential therapies available to modulate the inflammatory state in AF. (J Cardiovasc Electrophysiol, Vol. 21, pp. 1064-1070, September 2010) [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
9. A Randomized Cross-Over Study for Evaluation of the Effect of Image Optimization With Contrast on the Diagnostic Accuracy of Dobutamine Echocardiography in Coronary Artery Disease: The OPTIMIZE Trial.
- Author
-
Plana, Juan Carlos, Mikati, Issam A., Dokainish, Hisham, Lakkis, Nasser, Abukhalil, John, Davis, Robert, Hetzell, Brian C., and Zoghbi, William A.
- Subjects
ECHOCARDIOGRAPHY ,CORONARY disease ,HEMODYNAMICS ,VISUALIZATION - Abstract
Objectives: The purpose of this study was to evaluate whether the addition of a contrast agent to dobutamine stress echocardiography (DSE) improves its diagnostic accuracy for coronary artery disease (CAD) and to determine the effect of image quality on the diagnostic impact of contrast agent use in this setting. Background: Contrast agents can improve endocardial border definition. To date, however, there are no randomized trials that have evaluated the impact of contrast agent use on the accuracy of DSE. Methods: Patients referred for stress testing with dobutamine echocardiography underwent 2 DSE studies: 1 with and 1 without a contrast agent, at least 4 h apart in a randomized order and within a 24-h period. Results: A total of 101 patients underwent both DSE studies. Similar hemodynamics were achieved during the 2 stress testing sessions. The use of a contrast agent improved the percentage of segments adequately visualized at baseline (from 72 ± 24% to 95 ± 8%) and more so at peak stress (67 ± 28% to 96 ± 7%); both p < 0.001. Interpretation of wall motion with high confidence also increased with contrast agent use from 36% to 74% (p < 0.001). Segment visualization with the use of a contrast agent improved in all views, but was more pronounced in the apical views. In unenhanced DSE, 36% of studies were normal, 51% had ischemia, and 8% were uninterpretable—all of which became interpretable with the use of a contrast agent. When compared with angiography (n = 92; 55 patients with CAD), accurate detection of ischemia was higher with contrast-enhanced studies versus nonenhanced studies (p = 0.02). As endocardial visualization and confidence of interpretation decreased in unenhanced studies, a greater impact of the use of a contrast agent on DSE accuracy was observed (p < 0.01). Conclusions: During dobutamine stress echocardiography, contrast agent administration improves endocardial visualization at rest and more so during stress, leading to a higher confidence of interpretation and greater accuracy in evaluating CAD. The lesser the endocardial border visualization, the higher the impact of contrast echocardiography on accuracy. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
10. Ability of Minor Elevations of Troponins I and T to Predict Benefit From an Early Invasive Strategy in Patients With Unstable Angina and Non-ST Elevation Myocardial Infarction.
- Author
-
Morrow, David A., Cannon, Christopher P., Rifai, Nader, Frey, Martin J., Vicari, Ralph, Lakkis, Nasser, Robertson, Debbie H., Hille, Darcy A., DeLucca, Paul T., DiBattiste, Peter M., Demopoulos, Laura A., Weintraub, William S., and Braunwald, Eugene
- Subjects
CORONARY disease ,THERAPEUTICS ,PROGNOSIS ,HEALTH risk assessment - Abstract
Presents research testing whether an early invasive strategy provides greater benefit than a conservative strategy in acute coronary syndrome patients with elevated baseline troponin levels. Design, setting, and participants of the clinical trial conducted from December 1997 to June 2000; Interventions; Main outcome measure; Results; Conclusion that even small elevations in cardiac troponins I (cTnl) and T (cTnT) identify high-risk patients who benefit from an early invasive treatment strategy.
- Published
- 2001
- Full Text
- View/download PDF
11. Aspirin and Clopidogrel Response Variability.
- Author
-
Ferguson, Angela D., Dokainish, Hisham, and Lakkis, Nasser
- Subjects
- *
ASPIRIN , *ANTICOAGULANTS , *CORONARY disease , *HEMOGLOBINS , *DIABETES , *DRUG resistance , *TYPE 2 diabetes , *DISEASE relapse - Abstract
Antiplatelet resistance has been proposed as a possible mechanism to explain recurrent cardiovascular events in patients who have coronary artery disease and who are undergoing dual antiplatelet therapy. A comprehensive search on PubMed was conducted for literature that was printed in the English language between January 1996 and November 2007 on aspirin and clopidogrel resistance. Significant traits for aspirin hyporesponsiveness were female sex, older age, and lower levels of hemoglobin. Diabetes mellitus and elevated body mass index showed trends toward a higher incidence of resistance in some aspirin trials but did not reach statistical significance. Clopidogrel studies suggested that patients with type-2 diabetes mellitus are more likely to manifest inadequate response to the medication. Although 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors were initially suspected to decrease response to clopidogrel, later studies refuted this possibility. Patients with a suboptimal response to aspirin or clopidogrel seem to be at increased risk of recurrent cardiovascular events. Large clinical trials with standardized laboratory methods and well-defined protocols are needed to determine whether common features exist in patients with suspected hyporesponsiveness to antiplatelet therapy, and to validate the clinical relevance of response variability. A concise nonarbitrary definition of physiologic "resistance" is needed, and investigators should identify patients as having a variable response to antiplatelet therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2008
12. Reversible Cerebral Vasoconstriction Syndrome Associated with Coronary Artery Vasospasm.
- Author
-
Laeeq, Rida, Berman, Jeffrey S., Khalid, Umair, Lakkis, Nasser M., and Tabbaa, Rashed
- Subjects
- *
CORONARY vasospasm , *VASOCONSTRICTION , *CEREBRAL vasospasm , *CORONARY disease , *THERAPEUTICS , *SYNDROMES - Abstract
Reversible cerebral vasoconstriction syndrome is a rare disorder associated with neurologic symptoms secondary to diffuse cerebral vasospasm. Cardiac involvement in this disease is exceedingly rare. A 50-year-old woman was admitted to our hospital for evaluation of chest pain. During a 3-year period, she had been admitted multiple times because of chest pain and elevated serum cardiac enzymes. Transthoracic echocardiograms showed transient wall-motion abnormalities; however, coronary angiograms revealed no coronary artery disease. At the current admission, she had a thunderclap headache, and cerebral angiograms revealed diffuse cerebral vasoconstriction that improved after verapamil infusion, confirming the diagnosis of reversible cerebral vasoconstriction syndrome. The patient was treated successfully with oral diltiazem and had no recurrence of symptoms. We describe what we think is the first reported case of coronary artery spasm in association with reversible cerebral vasoconstriction syndrome. Future research should be focused on identifying treatment options and defining the mechanisms by which the cerebral and coronary vasculature are affected. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. Comparison by Meta-Analysis of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With a Mean Age of ≥70 Years.
- Author
-
Alam, Mahboob, Virani, Salim S., Shahzad, Saima A., Siddiqui, Sahar, Siddiqui, Khaleeq H., Mumtaz, Shahzad A., Kleiman, Neal S., Coselli, Joseph S., Lakkis, Nasser M., and Jneid, Hani
- Subjects
- *
ANGIOPLASTY , *CORONARY artery bypass , *HEALTH outcome assessment , *CORONARY disease , *RANDOM effects model , *LENGTH of stay in hospitals , *MYOCARDIAL infarction , *STROKE , *PATIENTS - Abstract
A paucity of published data evaluating the outcomes of older patients (age ≥70 years) undergoing revascularization for unprotected left main coronary artery disease is available. We performed aggregate data meta-analyses of the clinical outcomes (all-cause mortality, nonfatal myocardial infarction, stroke, repeat revascularization, and major adverse cardiac and cerebrovascular events at 30 days and 12 and 22 months) in studies comparing percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in patients with a mean age of ≥70 years and unprotected left main coronary artery disease. A comprehensive, time-unlimited literature search to January 31, 2013 identified 10 studies with a total of 2,386 patients (PCI, n = 909; CABG, n = 1,477). Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using the random-effects model. The patients in the PCI group were more likely than those in the CABG group to present with acute coronary syndrome (59.6% vs 44.8%, p <0.001). PCI was associated with a shorter hospital stay (4.2 - 0.8 vs 8.3 - 0.01 days, p <0.001). No significant differences were found between PCI and CABG for all cause-mortality, nonfatal myocardial infarction, and major adverse cardiac and cerebrovascular events at 30 days and 12 and 22 months. However, PCI was associated with lower rates of stroke at 30 days (OR 0.14, 95% CI 0.02 to 0.76) and 12 months (OR 0.14, 95% CI 0.03 to 0.60) and higher rates of repeat revascularization at 22 months (OR 4.34, 95% CI 2.69 to 7.01). These findings were consistent with the findings from a subgroup analysis of patients aged ≥75 years. In conclusion, older patients (age ≥70 years) with unprotected left main coronary artery disease had comparable rates of all-cause mortality, nonfatal myocardial infarction, and major adverse cardiac and cerebrovascular events after PCI or CABG. The patients undergoing PCI had a shorter hospital stay and lower rates of early stroke; however, they experienced higher repeat revascularization rates at longer term follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
14. A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents: The PROTECT–TIMI-30 Trial
- Author
-
Gibson, C. Michael, Morrow, David A., Murphy, Sabina A., Palabrica, Theresa M., Jennings, Lisa K., Stone, Peter H., Lui, Henry H., Bulle, Thomas, Lakkis, Nasser, Kovach, Richard, Cohen, David J., Fish, Polly, McCabe, Carolyn H., and Braunwald, Eugene
- Subjects
- *
HEART diseases , *MYOCARDIAL infarction , *CORONARY disease , *ISCHEMIA - Abstract
Objectives: The goal of this study was to evaluate glycoprotein IIb/IIIa inhibition with eptifibatide when administered with indirect thrombin inhibition as compared with monotherapy with direct thrombin inhibition with bivalirudin among patients with non–ST-segment elevation acute coronary syndromes (ACS). Background: The optimal combination of antiplatelet and antithrombin regimens that maximizes efficacy and minimizes bleeding among patients with non–ST-segment elevation ACS undergoing percutaneous coronary intervention (PCI) is unclear. Methods: A total of 857 patients with non–ST-segment elevation ACS were assigned randomly to eptifibatide + reduced dose unfractionated heparin (n = 298), eptifibatide + reduced-dose enoxaparin (n = 275), or bivalirudin monotherapy (n = 284). Results: Among angiographically evaluable patients (n = 754), the primary end point of post-PCI coronary flow reserve was significantly greater with bivalirudin (1.43 vs. 1.33 for pooled eptifibatide arms, p = 0.036). Thrombolysis In Myocardial Infarction (TIMI) myocardial perfusion grade more often was normal with eptifibatide treatment compared with bivalirudin (57.9% vs. 50.9%, p = 0.048). The duration of ischemia on continuous Holter monitoring after PCI was significantly longer among patients treated with bivalirudin (169 vs. 36 min, p = 0.013). There was no excess of TIMI major bleeding among patients treated with eptifibatide compared with bivalirudin (0.7%, n = 4 vs. 0%, p = NS), but TIMI minor bleeding was increased (2.5% vs. 0.4%, p = 0.027) as was transfusion (4.4% to 0.4%, p < 0.001). Conclusions: Among moderate- to high-risk patients with ACS undergoing PCI, coronary flow reserve was greater with bivalirudin than eptifibatide. Eptifibatide improved myocardial perfusion and reduced the duration of post-PCI ischemia but was associated with higher minor bleeding and transfusion rates. Ischemic events and biomarkers for myonecrosis, inflammation, and thrombin generation did not differ between agents. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
15. Comparison of Effects of Bare Metal Versus Drug-Eluting Stent Implantation on Biomarker Levels Following Percutaneous Coronary Intervention for Non–ST-Elevation Acute Coronary Syndrome
- Author
-
Gibson, C. Michael, Karmpaliotis, Dimitri, Kosmidou, Ioanna, Murphy, Sabina A., Kirtane, Ajay J., Budiu, Daniela, Ray, Kausik K., Herrmann, Howard C., Lakkis, Nasser, Kovach, Richard, French, William, Blankenship, James, Lui, Henry H., Palabrica, Theresa, Jennings, Lisa K., Cohen, David J., and Morrow, David A.
- Subjects
- *
SURGICAL stents , *THROMBOLYTIC therapy , *CORONARY disease , *MYOCARDIAL infarction - Abstract
Drug-eluting stents (DESs) deliver biphasic (early and late) elution of anti-inflammatory compounds. We therefore hypothesized that DESs would be associated with early reductions in inflammatory biomarker release after percutaneous coronary intervention (PCI). A total of 741 patients with non–ST-elevation acute coronary syndrome underwent PCI in the Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet and Anti-Thrombotic Agents (PROTECT) Thrombolysis In Myocardial Infarction 30 study of eptifibatide and reduced-dose antithrombin compared with bivalirudin. Serial biomarkers C-reactive protein, troponin, creatine kinase-MB, soluble CD40 ligand, interleukin-6, prothrombin fragment F1.2, and RANTES (regulated on activation, normal T-cell expressed and secreted) were assessed through 24 hours after PCI. DES use was at the investigator’s discretion. Patients treated with DESs (n = 665) versus bare metal stents (n = 139) were more likely to have patent arteries before PCI (92.0% vs 86.6%, p = 0.04), Thrombolysis In Myocardial Infarction myocardial perfusion grade 3 (57.9% vs 47.7%, p = 0.033), and the left anterior descending artery as the culprit artery (38.5% vs 18.3%, p <0.001). The increase in C-reactive protein and troponin was lower among patients undergoing DES implantation (median 2.1 vs 3.5 mg/L for C-reactive protein, median 0.11 vs 0.41 ng/ml for troponin), even after adjustment for randomized treatment, clopidogrel before treatment, diabetes mellitus status, epicardial patency, left anterior descending artery location, and myocardial perfusion (p = 0.036 and p = 0.039, respectively). Interleukin-6 was lower with DESs on univariate analysis but not multivariate analysis. Creatine kinase-MB, soluble sCD40 ligand, prothrombin fragment F1.2, and RANTES did not differ by DES use. In conclusion, patients undergoing DES implantation achieved more reductions in periprocedural markers of inflammation and necrosis than patients receiving bare metal stents among those with non–ST-elevation acute coronary syndrome. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
16. SHORT AND LONG TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION VERSUS CORONARY ARTERY BYPASS GRAFTING IN OLDER (>70 YEARS) PATIENTS WITH UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE IN THE ERA OF DRUG ELUTING STENTS.
- Author
-
Khan, Mahin, Kayani, Waleed, Dadu, Razvan, Virani, Salim, Hamzeh, Ihab, Jneid, Hani, Alam, Mahboob, El-Refai, Mostafa, and Lakkis, Nasser
- Subjects
- *
CORONARY disease , *PERCUTANEOUS coronary intervention , *CORONARY artery bypass , *HEALTH outcome assessment , *CORONARY heart disease treatment , *DRUG-eluting stents , *PATIENTS - Published
- 2016
- Full Text
- View/download PDF
17. RADIAL VERSUS FEMORAL ACCESS FOR PERCUTANEOUS CORONARY INTERVENTION IN NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A META-ANALYSIS OF 38,587 PATIENTS.
- Author
-
Pham, Don, Hoang, Vu, Addison, Daniel, Ahmed, Ameera, Hira, Ravi, Hamzeh, Ihab, Virani, Salim, Lakkis, Nasser, and Alam, Mahboob
- Subjects
- *
CORONARY disease , *MYOCARDIAL infarction , *FEMORAL artery , *META-analysis , *CARDIOLOGY periodicals - Published
- 2015
- Full Text
- View/download PDF
18. 884-5 Impact of troponin status and coronary artery disease by angiography on outcome in acute coronary syndrome: A TACTICS TIMI-18 substudy.
- Author
-
Pillai, Manu, DiBattiste, Peter, Murphy, Sabina, Morrow, David, Cannon, Christopher, and Lakkis, Nasser M
- Subjects
- *
CORONARY disease , *DIAGNOSIS , *CORONARY heart disease treatment , *CORONARY angiography , *TROPONIN , *NATRIURETIC peptides - Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.